DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.
The pathological hallmark of myelodysplastic syndromes (MDS) is marrow dysplasia, which representsthe basis of the WHO classification of these disorders. This classification provides clinicians with a useful tool for defining the different subtypes of MDS and individual prognosis. The WHO proposal has...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2017-02-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2821 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850084392494432256 |
|---|---|
| author | Matteo Della Porta Cristina Picone |
| author_facet | Matteo Della Porta Cristina Picone |
| author_sort | Matteo Della Porta |
| collection | DOAJ |
| description | The pathological hallmark of myelodysplastic syndromes (MDS) is marrow dysplasia, which representsthe basis of the WHO classification of these disorders. This classification provides clinicians with a useful tool for defining the different subtypes of MDS and individual prognosis. The WHO proposal has raised some concern regarding minimal diagnostic criteria particularly in patients with normal karyotype without robust morphological markers of dysplasia (such as ring sideroblasts or excess of blasts). Therefore, there is clearly a need to refine the accuracy to detect marrow dysplasia. Flow cytometry (FCM) immunophenotyping has been proposed as a tool to improve the evaluation of marrow dysplasia. Rationale for the application of FCM in the diagnostic work up of MDS is that immunophenotyping is an accurate method for quantitative and qualitative evaluation of hematopoietic cells and that MDS have been found to have abnormal expression of several cellular antigens. To become clinically applicable, FCM analysis should be based on parameters with sufficient specificity and sensitivity, data should be reproducible between different operators and the results should be easily understood by clinicians. In this review, we discuss the most relevant progresses in detection of marrow dysplasia by FCM in MDS |
| format | Article |
| id | doaj-art-368fa623591e4acfa3b4bfd91a4344da |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2017-02-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-368fa623591e4acfa3b4bfd91a4344da2025-08-20T02:44:03ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062017-02-0191e2017017e201701710.4084/mjhid.2017.0171668DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.Matteo Della Porta0Cristina PiconeProf. Matteo Giovanni Della Porta, MD, Cancer Center, Humanitas Research Hospital & Humanitas University, via Manzoni, 56 Rozzano – Milan, Italy. Phone +39 02 8224 7668; Fax +39 02 8224 4590; E-mail: matteo.della_porta@hunimed.euThe pathological hallmark of myelodysplastic syndromes (MDS) is marrow dysplasia, which representsthe basis of the WHO classification of these disorders. This classification provides clinicians with a useful tool for defining the different subtypes of MDS and individual prognosis. The WHO proposal has raised some concern regarding minimal diagnostic criteria particularly in patients with normal karyotype without robust morphological markers of dysplasia (such as ring sideroblasts or excess of blasts). Therefore, there is clearly a need to refine the accuracy to detect marrow dysplasia. Flow cytometry (FCM) immunophenotyping has been proposed as a tool to improve the evaluation of marrow dysplasia. Rationale for the application of FCM in the diagnostic work up of MDS is that immunophenotyping is an accurate method for quantitative and qualitative evaluation of hematopoietic cells and that MDS have been found to have abnormal expression of several cellular antigens. To become clinically applicable, FCM analysis should be based on parameters with sufficient specificity and sensitivity, data should be reproducible between different operators and the results should be easily understood by clinicians. In this review, we discuss the most relevant progresses in detection of marrow dysplasia by FCM in MDShttp://www.mjhid.org/index.php/mjhid/article/view/2821Myelodysplastic SyndromeFlow CytometryDiagnostic Tools |
| spellingShingle | Matteo Della Porta Cristina Picone DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES. Mediterranean Journal of Hematology and Infectious Diseases Myelodysplastic Syndrome Flow Cytometry Diagnostic Tools |
| title | DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES. |
| title_full | DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES. |
| title_fullStr | DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES. |
| title_full_unstemmed | DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES. |
| title_short | DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES. |
| title_sort | diagnostic utility of flow cytometry in myelodysplastic syndromes |
| topic | Myelodysplastic Syndrome Flow Cytometry Diagnostic Tools |
| url | http://www.mjhid.org/index.php/mjhid/article/view/2821 |
| work_keys_str_mv | AT matteodellaporta diagnosticutilityofflowcytometryinmyelodysplasticsyndromes AT cristinapicone diagnosticutilityofflowcytometryinmyelodysplasticsyndromes |